Chemistry:Motixafortide
From HandWiki
Short description: Medication
 | |
| Clinical data | |
|---|---|
| Trade names | Aphexda |
| Other names | BL-8040 |
| License data | |
| Routes of administration | Subcutaneous |
| Drug class | Antineoplastic |
| ATC code |
|
| Legal status | |
| Legal status | |
| Identifiers | |
| CAS Number |
|
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII |
|
| KEGG | |
| ChEBI | |
| Chemical and physical data | |
| Formula | C97H144FN33O19S2 |
| Molar mass | 2159.55 g·mol−1 |
Motixafortide, sold under the brand name Aphexda, is a medication used for the treatment of multiple myeloma.[1] Motixafortide is a hematopoietic stem cell mobilizer and a CXCR4 antagonist.[1] It is given by subcutaneous injection.[1]
Motixafortide was approved for medical use in the United States in September 2023.[3][4]
Medical uses
Motixafortide is indicated in combination with filgrastim, a granulocyte-colony stimulating factor (G-CSF), to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in people with multiple myeloma.[1][3]
Society and culture
Names
Motixafortide is the international nonproprietary name.[5]
References
- ↑ 1.0 1.1 1.2 1.3 1.4 "Aphexda- motixafortide injection, powder, lyophilized, for solution". 4 September 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f7cdc584-ebf0-a68e-e053-6294a90a9ea9.
- ↑ "Aphexda- motixafortide acetate injection, powder, lyophilized, for solution". 22 September 2023. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=065b582d-e5e5-eeec-e063-6394a90a5990.
- ↑ 3.0 3.1 "Aphexda approval letter". 8 September 2023. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2023/217159Orig1s000ltr.pdf.
This article incorporates text from this source, which is in the public domain.
- ↑ "BioLineRx Announces FDA Approval of Aphexda (motixafortide) in Combination with Filgrastim (G-CSF) to Mobilize Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Patients with Multiple Myeloma" (Press release). BioLineRx Ltd. 11 September 2023. Retrieved 13 September 2023 – via PR Newswire.
- ↑ "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information 33 (3). 2019.
Further reading
- "Motixafortide and G-CSF to mobilize hematopoietic stem cells for autologous transplantation in multiple myeloma: a randomized phase 3 trial". Nature Medicine 29 (4): 869–879. April 2023. doi:10.1038/s41591-023-02273-z. PMID 37069359.
External links
- Clinical trial number NCT03246529 for "A Phase III, Safety, Tolerability and Efficacy of Combination Treatment of BL-8040 and G-GSF as Compared to Placebo and G-CSF for thE MobilizatioN of HematopoiEtic Stem Cells for Autologous TransplantatIon in SubjectS With MM (GENESIS)" at ClinicalTrials.gov
 |  |
